Onyx Healthcare, Inc. AI Stock Analysis
Onyx Healthcare, Inc. (6569) AI Stock Analysis
Onyx Healthcare, Inc.
(TPEx:6569)
The score is primarily supported by a strong, conservatively financed balance sheet and positive cash generation, but weakened by significant profitability deterioration and declining cash-flow momentum. Technical conditions are bearish despite oversold readings, while valuation and dividend income provide moderate support.
Onyx Healthcare, Inc. (6569) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 3.40B
- Dividend Yield
- 3.77%
- Average Volume (3M)
- 33.14K
- Price to Earnings (P/E)
- 18.6
- Beta (1Y)
- 0.58
- Revenue Growth
- 3.93%
- EPS Growth
- 28.67%
- Country
- TW
- Employees
- 120
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Healthcare Information Services
Onyx Healthcare, Inc. Business Overview & Revenue Model
Company Description
Onyx Healthcare Inc. is a dedicated Taiwanese firm specializing in medical information technology. The company focuses on the entire lifecycle—from conceptual design and manufacturing to the commercial distribution—of medical computing hardware and p...
Onyx Healthcare, Inc. Financial Statement Overview
Summary
The strong balance sheet and low leverage support financial quality, but materially weaker profit margins, lower return on equity, and declining free cash flow moderate the score.
Income Statement
45NeutralBalance Sheet
85Very PositiveCash Flow
62Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.45B | 1.31B | 1.24B | 1.49B | 1.60B | 1.20B |
| Gross Profit | 477.22M | 434.02M | 456.27M | 556.14M | 472.31M | 363.73M |
| EBITDA | 103.86M | 74.05M | 164.37M | 332.78M | 271.07M | 170.68M |
| Net Income | 183.65M | 111.70M | 180.91M | 255.26M | 202.96M | 127.55M |
Balance Sheet | ||||||
| Total Assets | 2.36B | 2.15B | 2.11B | 2.05B | 1.97B | 1.70B |
| Cash, Cash Equivalents and Short-Term Investments | 267.98M | 382.50M | 332.83M | 409.78M | 336.10M | 193.02M |
| Total Debt | 387.16M | 292.84M | 250.98M | 206.74M | 191.92M | 315.55M |
| Total Liabilities | 813.54M | 583.59M | 553.43M | 527.66M | 566.02M | 667.17M |
| Stockholders Equity | 1.55B | 1.57B | 1.54B | 1.51B | 1.39B | 1.03B |
Cash Flow | ||||||
| Free Cash Flow | -48.74M | 149.87M | 117.43M | 282.51M | 146.74M | -278.77M |
| Operating Cash Flow | -30.20M | 164.16M | 124.52M | 350.49M | 161.79M | 17.13M |
| Investing Cash Flow | -94.83M | -32.51M | -52.98M | -184.36M | -31.03M | -332.06M |
| Financing Cash Flow | 3.14M | -79.95M | -120.67M | -128.54M | 6.03M | 109.89M |
Onyx Healthcare, Inc. Peers Comparison
Overall Rating
TW:304671Outperform
TW:355664Neutral
TW:656963Neutral
TW:359449Neutral
TW:661243Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 71Outperform | TWD 3.92B | 10.16 | ― | 5.96% | 31.68% | 27.27% | |
| 64Neutral | TWD 3.65B | 14.40 | ― | 3.15% | 27.26% | 133.00% | |
| 63Neutral | TWD 3.44B | 18.64 | ― | 3.77% | 3.93% | 28.67% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 49Neutral | TWD 3.85B | 33.07 | ― | 0.95% | 30.92% | 271.46% | |
| 43Neutral | TWD 3.60B | 33.24 | ― | 0.44% | 12.00% | 2.68% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:6569 | Onyx Healthcare, Inc. | 79.60 | -26.95 | -25.29% | |
| TW:3046 | Aopen Incorporated | 50.30 | 4.11 | 8.91% | |
| TW:3556 | eGalax_eMPIA Technology Inc. | 61.90 | 24.14 | 63.93% | |
| TW:3594 | ARBOR Technology Corp. | 41.90 | 2.16 | 5.44% | |
| TW:6612 | ICARES Medicus Inc | 68.50 | -9.76 | -12.47% | |
| TW:7821 | Mitac Digital Technology Corporation | 31.45 | -26.70 | -45.91% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026
